stockmarketproxy
/
VRTXNasdaq SEC EDGAR

VERTEX PHARMACEUTICALS INC / MA

Pharmaceutical Preparations·BOSTON, MA·FY end 12/31·CIK 875320
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$12.0B$11.0B$9.9B$8.9B$7.6B
Gross Profit——————
Operating Income$4.2B-$232.9M$3.8B$4.3B$2.8B
Net Income$4.0B-$535.6M$3.6B$3.3B$2.3B
Operating CF$3.6B-$492.6M$3.5B$4.1B$2.6B
Capex$437.6M$297.7M$200.4M$204.7M$235.0M
Free Cash Flow$3.2B-$790.3M$3.3B$3.9B$2.4B
Buybacks$2.0B$1.2B$427.6M$0$1.4B
Dividends——————
Gross Margin——————
Operating Margin34.8%-2.1%38.8%48.2%36.7%
Net Margin32.9%-4.9%36.7%37.2%30.9%
FCF Margin26.6%-7.2%33.8%44.0%31.8%
R&D / Revenue————40.3%—
Effective Tax14.9%315.5%17.4%21.5%14.2%
Debt / Equity——————
Buybacks / FCF63.2%-148.9%12.8%0.0%59.2%

Peer comparison

Pharmaceutical Preparations · 5 peers
CEO Pay Ratio
VRTX
80:1
ROIV
518:1
AXSM
23:1
COGT
95:1
PFE
277:1
ABT
166:1
CEO total comp
VRTX
$21M
ROIV
$163M
AXSM
$34M
COGT
$28M
PFE
$28M
ABT
$24M
Net Margin
VRTX
32.9%
ROIV
-592.0%
AXSM
-28.7%
COGT
—
PFE
12.4%
ABT
14.7%